Dr. Martens PLC Technical change in Permira ownership structure

RNS Number : 2034S

Dr. Martens PLC

12 June 2024

 

 

12 June 2024

Dr. Martens plc

                                                                                                                                                  

Technical change in Permira ownership structure

 

Dr. Martens plc ('the Company') makes this announcement in connection with the TR-1 announcements released today regarding the notification of major holdings by IngreGrsy Limited and IngreLux S.àr.l..

Permira V Fund has undergone a restructure of its holding of shares in Dr. Martens plc, whereby IngreGrsy Limited (a newly incorporated Guernsey company) has replaced IngreLux S.àr.l. (a Luxembourg entity) in the Permira Fund V structure and IngreLux S.àr.l has transferred its 38.46% shareholding in the Company to IngreGrsy Limited.  As a result, IngreGrsy Limited replaced IngreLux S.àr.l. as the Company's largest shareholder with effect from 11 June 2024. The Company, IngreLux S.àr.l. and IngreGrsy Limited also entered into a novation agreement in order for IngreGrsy Limited to replace IngreLux S.à r.l. in the relationship agreement with the Company.  The Permira V Fund ownership structure is otherwise unchanged and remains ultimately controlled by Permira V GP Limited and advised by Permira Advisers LLP.

 

 

Enquiries

Investors and analysts                                                                     

Bethany Barnes, Director of Investor Relations           [e-mail]   [phone]

Beth Callum, Investor Relations Manager  [e-mail]                          [phone]

 

Company Secretariat

Paul Rolling, Assistant Company Secretary   [e-mail]

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

MSCQKBBNPBKDBAD